← Back to headlines
Sarepta reiterates 2026 revenue guidance and targets Cohort 8 data
Sarepta Therapeutics has reiterated its net product revenue guidance of $1.2 billion to $1.4 billion for 2026, while also aiming to release Cohort 8 data by the end of the year.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Study Finds Secondhand Smoke Caused Nearly 1.7 Million Deaths Globally
2h ago
Indonesia Suspends Nearly 2,000 Free Meal Kitchens Over Sanitation Violations
2h ago
Pamela Anderson Opens Up About Her 1990s Hepatitis C Diagnosis and Recovery
7h ago
Teen Girl Intubated After Electric Scooter Crash in Tinos
17h ago